Week of August 27, 2012: AstraZeneca Names Pascal Soriot CEO; The Merck Group Agrees to Acquire Biochrom; and More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of August 27, 2012: AstraZeneca Names Pascal Soriot CEO; The Merck Group Agrees to Acquire Biochrom; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

AstraZeneca has appointed Pascal Soriot as CEO and executive director of the company’s board of directors, effective Oct. 1, 2012. Simon Lowth will remain as AstraZeneca’s interim CEO until Soriot joins. At that point, Lowth will resume his responsibilities as chief financial officer and will continue to serve as an executive director on the board. Read More

Eli Lilly announced that the US Court of Appeals for the Federal Circuit has affirmed a prior ruling by the US District Court for the District of Delaware that the company’s compound patent for Alimta (pemetrexed) is valid. The compound patent provides protection for Alimta in the US through January 2017. Read More

The Merck Group has agreed to acquire Biochrom, a German company that specializes in the production and marketing of cell-culture media and buffer solutions. The acquisition is expected to close in the fourth quarter of 2012, and is subject to customary closing conditions and regulatory approval. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
15%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here